home / stock / amlx / amlx quote
Last: | $2.03 |
---|---|
Change Percent: | -2.5% |
Open: | $2.05 |
Close: | $2.03 |
High: | $2.13 |
Low: | $2 |
Volume: | 1,473,737 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.03 | $2.05 | $2.03 | $2.13 | $2 | 1,473,737 | 05-03-2024 |
$2 | $1.96 | $2 | $2.05 | $1.93 | 1,911,403 | 05-02-2024 |
$1.93 | $1.82 | $1.93 | $1.975 | $1.8 | 1,793,175 | 05-01-2024 |
$1.81 | $1.92 | $1.81 | $1.97 | $1.81 | 1,882,747 | 04-30-2024 |
$1.9 | $1.79 | $1.9 | $1.98 | $1.76 | 2,101,194 | 04-29-2024 |
$1.76 | $1.79 | $1.76 | $1.84 | $1.7 | 5,218,046 | 04-26-2024 |
$1.78 | $1.87 | $1.78 | $1.91 | $1.76 | 2,479,181 | 04-25-2024 |
$1.88 | $1.97 | $1.88 | $1.99 | $1.87 | 1,403,687 | 04-24-2024 |
$1.95 | $1.97 | $1.95 | $2.02 | $1.94 | 1,470,442 | 04-23-2024 |
$1.98 | $1.9 | $1.98 | $2.025 | $1.9 | 1,555,644 | 04-22-2024 |
$1.87 | $1.98 | $1.87 | $2.02 | $1.85 | 2,503,582 | 04-19-2024 |
$1.98 | $2.01 | $1.98 | $2.0299 | $1.955 | 1,034,036 | 04-18-2024 |
$2 | $2.04 | $2 | $2.08 | $1.99 | 1,734,078 | 04-17-2024 |
$2.01 | $2.07 | $2.01 | $2.07 | $1.98 | 2,157,902 | 04-16-2024 |
$2.07 | $2.1 | $2.07 | $2.14 | $1.99 | 3,707,247 | 04-15-2024 |
$2.1 | $2.28 | $2.1 | $2.29 | $2.07 | 2,824,749 | 04-12-2024 |
$2.29 | $2.45 | $2.29 | $2.56 | $2.25 | 3,735,005 | 04-11-2024 |
$2.46 | $2.6 | $2.46 | $2.65 | $2.45 | 3,170,215 | 04-10-2024 |
$2.67 | $2.67 | $2.67 | $2.82 | $2.62 | 1,957,529 | 04-09-2024 |
$2.69 | $2.65 | $2.69 | $2.87 | $2.61 | 2,224,544 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its first quarter 2024 financial results on Thursday, May 9, 2024. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the f...
- I nterim analysis, including eight participants assessed at Week 24, demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with disease progression - All eig...
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 08, 2024 (GLOBE NEWSWIRE) -- The Po...